AI Case Study

Action Against AMD and Benevolent AI aim to find treatments for age-related macular degeneration (AMD) that causes blindness using machine learning

Benevolent AI and a group of four charities, Blind Veterans UK, Fight for Sight, the Macular Society and Scottish War Blinded, have partnered to find treatments and a potential cure for AMD. Benevolent AI's machine learning technology will be leveraged to analyse existing scientific papers, clinical trials information, images, formulas, patents and any other knowledge we have on age-related macular degeneration (AMD) to uncover potential patterns, connections and point researchers towards important research areas.

Industry

Healthcare

Healthcare Providers And Services

Project Overview

"BenevolentAI is collaborating with a group of four charities partnering to find a cure for AMD. Blind Veterans UK, Fight for Sight, the Macular Society and Scottish War Blinded have formed Action Against AMD to increase the funding for research into the condition and specifically to help develop an intervention that stops people losing their sight from AMD.

BenevolentAI will use its proprietary technology platform to comprehensively review and understand the millions of scientific papers, clinical trials information, images, formulas, patents and additional data sets relating to AMD. The technology will then conduct complex reasoning to create a new understanding of the disease, learn, explore, create and translate what it has learnt from this vast volume of information to pin-point important research areas, possible ways of preventing AMD and potential treatments."

Reported Results

Research; results not yet available

Technology

"BenevolentAI combines the power of computational medicine and advanced AI with the principles of open systems and cloud computing to transform the way medicines are designed, developed, tested and brought to market."

Function

R And D

Product Development

Background

"AMD is the main cause of sight loss in developed countries and the third biggest worldwide. In the UK more than 600,000 have late stage AMD and this is set to double by 2050 as people live longer. Many more older people have early AMD that does not yet affect their sight so finding ways to detect and treat the disease before it causes sight loss is vital."

Benefits

Data

Scientific papers, clinical trials information, images, formulas, patents and additional data sets relating to AMD